Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSCTPI-2 is an inhibitor of the mitochondrial citrate transporter, also known as SLC25A1.1 It decreases the oxygen consumption rate (OCR) in tumor spheres isolated from patients with non-small cell lung cancer (NSCLC) and inhibits the invasion of lung cancer stem cells in vitro. CTPI-2 (50 µM) acts synergistically with cisplatin (Item No. 13119) to reduce the viability of cisplatin-resistant patient-derived NSCLC cells. It reverses increases in body weight, steatosis, and fasting blood glucose levels in a mouse model of high fat diet-induced non-alcoholic fatty liver disease (NAFLD) when administered at a dose of 50 mg/kg.2
WARNING This product is not for human or veterinary use.
1. The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-
2. Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. Cell Death Differ. 27(7), 2143-2157 (2020).